Boasting new discoveries from Xtandi, Erleada inventors, ORIC pitches $86M IPO on cancer drugs targeted at resistance
Months after kicking off Phase Ib trials, a group of seasoned cancer drug developers out of the Bay Area have filed for an $86 million IPO in anticipation of a preliminary look on whether their glucocorticoid receptor antagonist works against prostate cancer and other solid tumors.
As ORIC Pharmaceuticals’ name — which is actually an acronym — suggests, the company wants to “overcome resistance in cancer.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.